Unlike other antidiabetic agents, the glucose lowering effect of SGLT2 inhibitors is independent of pancreatic beta-cell function and insulin sensitivity – an ideal property in the context of T2DM disease progression [11] and metabolic milieu of the T2DM phenotype [12]. Here, INS is linked to type 2 diabetes mellitus.